Chlorozinc(1+);[(E)-hept-3-en-4-yl]-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]azanide
C13H25ClN2OZn — CID 10806021
Data last refreshed: (MolForge compound catalog, from PubChem)
About Chlorozinc(1+);[(E)-hept-3-en-4-yl]-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]azanide
Chlorozinc(1+);[(E)-hept-3-en-4-yl]-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]azanide (PubChem CID 10806021) has the molecular formula C13H25ClN2OZn and a molecular weight of 326.20 g/mol. Its IUPAC name is chlorozinc(1+);[(E)-hept-3-en-4-yl]-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]azanide.
Molecular Properties
| Compound Name | Chlorozinc(1+);[(E)-hept-3-en-4-yl]-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]azanide |
|---|---|
| PubChem CID | 10806021 |
| Molecular Formula | C13H25ClN2OZn |
| Molecular Weight | 326.20 g/mol |
| Exact Mass | 324.09 |
| IUPAC Name | chlorozinc(1+);[(E)-hept-3-en-4-yl]-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]azanide |
| SMILES | CC/C=C(\CCC)[N-]N1CCC[C@H]1COC.Cl[Zn+] |
| InChI | InChI=1S/C13H25N2O.ClH.Zn/c1-4-7-12(8-5-2)14-15-10-6-9-13(15)11-16-3;;/h7,13H,4-6,8-11H2,1-3H3;1H;/q-1;;+2/p-1/b12-7+;;/t13-;;/m0../s1 |
| InChIKey | ADNUJJDTCQJQGU-VDHJBGAKSA-M |
| XLogP | 4.17 |
| TPSA | 26.57 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 2 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 18 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 326.20 |
| LogP ≤ 5 | 4.17 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 2 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'heavy_metal', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 10806021 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.